- 首页
- DNA/RNA Synthesis
- Leflunomide-d4
Leflunomide-d4
An internal standard for the quantification of leflunomide
此产品仅用于科学研究，我们不为任何个人用途提供产品和服务
-
包装价格促销价数量
-
500ug￥3087.002470.00- +
-
1mg￥5187.004150.00- +
- 货号: ajcx22810
- CAS: 1189987-23-2
- 别名: 来氟米特 d4
- 分子式: C12H5D4F3N2O2
- 分子量: 274.2
- 纯度: ＞98%
- 溶解度: DMSO: soluble,Methanol: soluble
- 储存: Store at -20°C
- 库存: 现货
Background
Leflunomide-d4 is intended for use as an internal standard for the quantification of leflunomide by GC- or LC-MS. Leflunomide is a synthetic isoxazol and a prodrug form of A-771726 , a dihydroorotate dehydrogenase inhibitor.1 Leflunomide inhibits de novo pyrimidine synthesis to regulate T lymphocyte progression through the cell cycle. It inhibits proliferation and activation of T cells when used at concentrations of 25 and 100 µM, respectively, for na?ve and memory CD4+ T cells.2 It also reduces the production of Th1 effector cells and increases differentiation of Th2 cells in vitro and in splenocytes isolated from KLH-immunized mice. Leflunomide (35 mg/kg per day) reduces and prevents inflammation in a proteoglycan-induced mouse model of rheumatoid arthritis.3 Formulations containing leflunomide have been used in the treatment of active rheumatoid arthritis.
1.Breedveld, F.C., and Dayer, J.-M.Leflunomide: Mode of action in the treatment of rheumatoid arthritisAnn. Rheum. Dis.59(11)841-849(2000) 2.Dimitrova, P., Skapenko, A., Herrmann, M.L., et al.Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiationJ. Immunol.169(6)3392-3399(2002) 3.Glant, T.T., Mikecz, K., Bartlett, R.R., et al.Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomideImmunopharmacology23(2)105-116(1992)
